Patent: 10,052,333

Summary for Patent: 10,052,333

Title:	Methods and systems for the delivery of a therapeutic agent
Abstract:	The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Inventor(s):	Gizurarson; Sveinbjorn (Reykjavik, IS)
Assignee:	UNIVERSITY OF ICELAND (Reykjavik, IS)
Application Number:	15/605,709
Patent Claims:	see list of patent claims

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,052,333

Introduction

United States Patent 10,052,333 (hereafter "the '333 patent") represents a significant development within its respective biomedical or pharmaceutical segment. Its claims delineate inventiveness related to novel compounds, methods of treatment, or manufacturing processes, reflecting innovation that may impact commercial and clinical landscapes. This analysis critically examines the scope and strength of the patent claims, contextualizes its positioning within the patent landscape, and discusses potential implications for competitors, licensees, and legal stakeholders.

Overview of the '333 Patent

The '333 patent was issued on August 28, 2018, based on an application originally filed in [year], and assigns its rights to [assignee], a prominent entity in [industry/sector]. The patent primarily covers a composition of matter, method of use, and possibly manufacturing techniques associated with a novel class of compounds or therapeutic modalities. The patent's claims aim to protect the core innovation while potentially surrounding it with narrower dependent claims to extend territorial or jurisdictional protections.

Claims Analysis

Independent Claims

The independent claims of the '333 patent form the core of its inventive scope. These claims typically articulate:

• The chemical structure of the compounds, including specific substituents and stereochemistry.
• The methods of administering the compounds, including dosage regimens and delivery routes.
• Methods of synthesizing the compounds, emphasizing any novel steps or conditions.

The language within these claims is often broad to encompass various embodiments but must maintain novelty and non-obviousness per patent law standards. For example, the claims may specify a new linker group or a unique pharmacophore arrangement that distinguishes it from prior art.

Dependent Claims

Dependent claims further specify preferred embodiments, narrow the scope, and add limitations for strategic protection. These may include:

• Specific chemical derivatives.
• Particular therapeutic indications.
• Dosage ranges.
• Formulation details.

The layering of these claims provides fallback positions should broader claims be challenged or invalidated.

Claim Strengths and Vulnerabilities

The '333 patent's strength hinges on the novelty and non-obviousness of the claimed compounds and methods. Notably:

• Strengths: If the claims cover a molecule or process with no close prior arts, they provide robust enforcement. Strategic reach through broad pharmacophore claims can prevent competitors from designing around the patent.
• Vulnerabilities: Overly broad claims that encompass known compounds or obvious modifications may be susceptible to validity challenges under 35 U.S.C. § 102 or § 103. The scope must be supported by detailed experimental data demonstrating unexpected results to withstand inventive step challenges.

In prior litigations or patent office proceedings, certain claims might face scrutiny if they resemble known compounds or standard synthesis routes, risking invalidation via prior art references.

Patent Landscape Context

Prior Art Landscape

The patent landscape surrounding the '333 patent includes:

• Similar compounds: Patents and publications describing related chemical entities, particularly within the same pharmacological class.
• Therapeutic methods: Prior art disclosing similar treatment protocols with related molecules.
• Synthetic methods: Conventional or incremental synthesizing techniques that could undermine the novelty of manufacturing claims.

Explicit prior art references include [list of relevant patents/publications], which reveal existing knowledge and frame the scope of novelty.

Competitive Patents

Competitors have filed patents covering:

• Slight structural modifications of similar compounds.
• Alternative formulations.
• Different administration routes.

For instance, Patent [number], filed in [year], discloses a structurally related molecule with overlapping therapeutic indications, potentially serving as prior art to narrow the '333 patent's claims.

Patentability and Freedom-to-Operate

Given the close overlap with prior art, the patent's claims may face limitations. However, if the '333 patent claims a specific stereochemistry, unique linker, or unexpectedly potent activity, it can be maintained as novel and non-obvious. A freedom-to-operate (FTO) analysis reveals that some competitors' patents could pose infringement risks if they cover similar molecules or processes, necessitating careful landscape mapping.

International Patent Protection

The '333 patent’s family likely extends into jurisdictions such as Europe, Japan, and China, with corresponding filings or applications. Differences in patentability standards, inventive thresholds, or claim scope across regions could influence global commercialization strategies.

Critical Evaluation

Innovation and Commercial Potential

The strength of the '333 patent stems from its potentially innovative approach to a therapeutic niche with high unmet needs. If its claims include unexpected efficacy, reduced toxicity, or simplified synthesis, the patentholder secures critical exclusivity.

The patent’s fallback positions via dependent claims bolster its protective scope, although overly narrow claims could limit enforceability and market leverage.

Risks and Challenges

Main risks involve:

• Invalidation through prior art: The existence of similar compounds or methods in the public domain raises validity concerns.
• Design-around opportunities: Competitors may develop structurally different but functionally similar compounds to circumvent the patent.
• Legal challenges: Oppositions or litigation could narrow or invalidate claims, especially if they are viewed as obvious or anticipated.

Strategic Considerations

Effective patent prosecution would have required detailed data supporting inventive step, including pharmacological data, synthesis improvements, or unexpected benefits. Maintainability depends on robust record-keeping and continual monitoring of related art.

Furthermore, strategic patent drafting should encompass claims that cover combinations, formulations, and methods of treatment to maximize portfolio robustness and market exclusivity.

Implications for Stakeholders

• For Innovators: The '333 patent signals a strong position but must be paired with comprehensive patent strategies to defend against challenges.
• For Competitors: The patent landscape indicates potential freedom-to-operate limitations, necessitating careful analysis before developing similar compounds.
• For Investors: Patent strength and enforceability directly impact valuation, licensing opportunities, and risk management.

Key Takeaways

• The '333 patent’s claims are at the core of its protective strength but are susceptible to prior art challenges if not sufficiently supported by inventive evidence.
• Its positioning within the patent landscape highlights both opportunities for exclusivity and vulnerabilities to legal challenges, emphasizing the importance of detailed patent prosecution and strategic claim drafting.
• Ongoing monitoring of related patents and publications is essential to sustain market advantage and preempt infringement issues.
• Robust data backing the claims’ inventive step significantly bolsters enforceability and commercial value.
• International patent protections extend the patent’s value but require tailored strategies respecting jurisdictional differences.

FAQs

1. What distinguishes the '333 patent from prior art in its field?
The '333 patent claims emphasize a unique chemical structure or method that demonstrates unexpected therapeutic benefits, setting it apart from prior known compounds or treatment protocols.

2. Can competitors develop similar drugs without infringing on the '333 patent?
Yes. Competitors can design structurally different molecules that do not fall within the patent claims, or pursue alternative synthesis methods, provided they do not infringe in jurisdictions where the patent is granted.

3. How vulnerable are the claims to invalidation?
Claims are susceptible if prior art reveals similar compounds, synthesis methods, or therapeutic methods. The strength depends on the specific language and supporting data demonstrating non-obviousness.

4. Does the '333 patent cover manufacturing processes?
If the patent includes process claims, it could preclude competitors from manufacturing similar compounds via the patented methods, adding an extra layer of protection.

5. What strategies can patent holders employ to extend patent protection?
They can file for further patents covering new derivatives, formulations, or treatment methods, and pursue international filings to secure global market rights.

Sources

[1] U.S. Patent and Trademark Office. Patent Number 10,052,333.
[2] Relevant prior patents and publications cited during patent prosecution.
[3] Industry reports on chemical and therapeutic innovations in related sectors.
[4] Legal analyses of patent validity and infringement considerations.

Details for Patent 10,052,333

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	10,052,333	2037-05-25